Dulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i
2024

Dulaglutide and Dapagliflozin Improve Heart and Blood Vessel Function in Diabetes

Sample size: 60 publication 10 minutes Evidence: moderate

Author Information

Author(s): Emmanouil Korakas, John Thymis, Evangelos Oikonomou, Konstantinos Mourouzis, Aikaterini Kountouri, Loukia Pliouta, Sotirios Pililis, George Pavlidis, Stamatios Lampsas, Konstantinos Katogiannis, Lina Palaiodimou, Georgios Tsivgoulis, Gerasimos Siasos, Ignatios Ikonomidis, Athanasios Raptis, Vaia Lambadiari, Alessandro Delitala

Primary Institution: Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Greece

Hypothesis

The combination of dulaglutide and dapagliflozin will improve endothelial glycocalyx, arterial stiffness, myocardial function, and albuminuria compared to DPP-4 inhibitors in patients with T2DM and albuminuria.

Conclusion

The combination treatment of dulaglutide and dapagliflozin significantly improved heart and blood vessel function compared to DPP-4 inhibitors in patients with type 2 diabetes and albuminuria.

Supporting Evidence

  • Dual therapy showed greater improvements in endothelial glycocalyx and arterial stiffness compared to DPP-4 inhibitors.
  • After 12 months, the combination treatment significantly reduced urine albumin-to-creatinine ratio.
  • Both treatments improved myocardial function, but the dual therapy had a significantly higher effect.

Takeaway

This study shows that using two diabetes medications together can help make your heart and blood vessels work better, especially for people with diabetes and kidney problems.

Methodology

60 patients with T2DM and albuminuria were randomized to receive either dulaglutide and dapagliflozin or DPP-4 inhibitors for 12 months, with various health markers measured at baseline, 4 months, and 12 months.

Limitations

The study had a small sample size and did not directly compare different DPP-4 inhibitors.

Participant Demographics

60 patients, 48 males and 12 females, mean age 61 years.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.3390/jcm13247497

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication